Orchard Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	120.75	91.14	88.08	72.4
Depreciation & Amortization	38.39	33.39	29.04	31.14
Other Amortization	6.59	3.18	4.41	4.04
Loss (Gain) From Sale of Assets	-0.23	-	-	-
Loss (Gain) From Sale of Investments	-3.82	-0.55	0.41	-0.41
Other Operating Activities	-2.69	-5.18	-4.24	10.35
Change in Accounts Receivable	-10.94	26.88	-29.45	-9.27
Change in Inventory	-44.3	-35.06	-18.9	-26.12
Change in Accounts Payable	46.39	-13.8	34.85	19.32
Change in Unearned Revenue	16.52	16.77	22.25	89.35
Change in Other Net Operating Assets	-2.13	-3.49	6.4	7.48
Operating Cash Flow	164.54	113.29	132.86	198.28
Operating Cash Flow Growth	45.23%	-14.73%	-32.99%	-
Capital Expenditures	-54.35	-60.83	-49.1	-40.76
Sale of Property, Plant & Equipment	1.65	-	-	-
Sale (Purchase) of Intangibles	-40	-29.5	-21.69	-8.4
Investment in Securities	-100.68	-0.31	-0.25	1.64
Investing Cash Flow	-193.39	-90.64	-71.03	-47.52
Long-Term Debt Issued	-	-	75	-
Long-Term Debt Repaid	-15.73	-11.67	-74.95	-126.14
Net Debt Issued (Repaid)	-15.73	-11.67	0.05	-126.14
Issuance of Common Stock	194.22	-	-	-
Common Dividends Paid	-	-6.5	-	-
Other Financing Activities	-4.67	-0.87	-	-
Financing Cash Flow	173.82	-19.04	0.05	-126.14
Net Cash Flow	144.97	3.62	61.87	24.62
Free Cash Flow	110.18	52.46	83.76	157.52
Free Cash Flow Growth	110.02%	-37.36%	-46.83%	-
Free Cash Flow Margin	9.20%	4.91%	9.37%	21.34%
Free Cash Flow Per Share	0.33	0.17	0.27	0.51
Cash Interest Paid	5.21	5.62	3.06	3.61
Cash Income Tax Paid	29.5	32.54	25.18	2.37
Levered Free Cash Flow	48.99	-9.63	58.91	-
Unlevered Free Cash Flow	52.2	-6.17	60.91	-
Change in Net Working Capital	-8.3	29.99	-28.16	-

Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.